What it is
Jalupro Young Eye is an injectable, sterile, re-absorbable solution (gel) with sodium hyaluronate, amino acids and peptides for the periorbital area. It is supplied as one single-use glass syringe of 1 ml.
Intended use (per instructions for use)
Indicated for the treatment of crow's feet, bags, dark circles and reduction of puffiness in the periorbital area. The product supports the restoration of physiological conditions of elasticity in the area and acts as a tissular lubricant that can minimise the evidence of periorbital wrinkles, bags and dark circles. It is a gel for skin imperfections of mild to moderate entity; the more marked the defects, the more its efficacy and duration are reduced. It can be used concomitantly with physical or chemical treatments, such as peeling, laser therapy and dermabrasion.
Composition
Sodium hyaluronate, glycine, L-proline, L-leucine, L-lysine HCl, L-alanine, L-valine, L-arginine, acetyl decapeptide-3, oligopeptide-24, acetyl tetrapeptide-5, phosphate buffer, water for injection.
Treatment
- Contents: 1 pre-filled 1 ml glass syringe with sterile gel. The package does not contain needles.
- Needle: sterile needle with Luer-Lock connection; the choice of needle is up to the physician, and the manufacturer suggests 30G.
- Injection: intradermally, and the manufacturer recommends the deep dermis. The area is sterilised before treatment, and an anaesthetic cream can be applied about 30 minutes before. Insert the needle along the furrow and withdraw it gradually while delivering the gel; inject slowly and avoid excessive amounts. Light massage if needed. The dosage is up to the physician, and the treatment must not be repeated before three days have passed. See the instructions for use for the recommended treatment course.
Important to know
For use only by physicians. Contraindicated in case of known hypersensitivity to the components, in skin irritation or inflammatory processes in progress in the area to be treated, and in patients predisposed to coagulation disorders. In pregnancy and lactation the treatment should only be performed at the physician's discretion after a careful anamnesis. Do not inject into veins, do not mix with other implants or injectable products, do not re-sterilise and do not freeze. The product is for single use, one patient and one session. Rarely, local reactions (oedema, heating sensation, itching) may occur and normally resolve spontaneously within two days; infection is more rare. Do not expose the treated area to sources of heat until swelling has reabsorbed. Unused product and the used needle are disposed of as hospital waste.
Storage and shelf life
Store dry and protected from sunlight. Do not freeze. The expiry date refers to the unopened and correctly stored product. The manufacturer states no temperature limit.
Documentation and traceability
Medical device, CE 0373 (Directive 93/42/EEC). Manufacturer: Professional Derma SA, Lugano, Switzerland. EC representative: QUASER S.r.l., Rome, Italy. Made in Italy. See the attached Norwegian instructions for use (BC translation rev. 01, 26.10.2026). The additional label in the package is attached to the patient file.
